Piramal Pharma shares in focus after US FDA issues six observations for Mumbai facility

Piramal Pharma shares will be in focus after the US FDA's GMP inspection at its Turbhe facility from February 11-17, 2025, resulting in a Form 483 with six observations. The company confirmed that these relate to procedural improvements, not data integrity. Additionally, Piramal reported a 13% YoY revenue growth in Q3FY25, with a strong target price outlook.